APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 170 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,387 | +1069.7% | 40,641 | +316.9% | 0.03% | +575.0% |
| Q2 2023 | $888 | +38.1% | 9,749 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $643 | +27.6% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $504 | -99.9% | 9,749 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $666,000 | +51.0% | 9,749 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $441,000 | -10.9% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $495,000 | +7.4% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $461,000 | +43.6% | 9,749 | 0.0% | 0.00% | +100.0% |
| Q3 2021 | $321,000 | -47.9% | 9,749 | 0.0% | 0.00% | -66.7% |
| Q2 2021 | $616,000 | +47.4% | 9,749 | 0.0% | 0.00% | +50.0% |
| Q1 2021 | $418,000 | -25.1% | 9,749 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $558,000 | +89.8% | 9,749 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $294,000 | -7.5% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $318,000 | +21.8% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $261,000 | – | 9,749 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 1,526,122 | $29,759,000 | 24.10% |
| Cormorant Asset Management, LP | 3,600,000 | $70,200,000 | 4.74% |
| SECTORAL ASSET MANAGEMENT INC | 1,727,829 | $33,693,000 | 4.05% |
| Hillhouse Capital Management | 2,098,581 | $40,922,000 | 1.71% |
| HHLR ADVISORS, LTD. | 2,579,708 | $50,304,000 | 1.40% |
| CLOUGH CAPITAL PARTNERS L P | 589,734 | $11,500,000 | 1.01% |
| Vivo Capital, LLC | 383,538 | $7,479,000 | 0.75% |
| Opaleye Management Inc. | 115,000 | $2,243,000 | 0.62% |
| Virtus ETF Advisers LLC | 14,338 | $280,000 | 0.60% |
| Eversept Partners, LP | 104,349 | $2,034,806 | 0.59% |